117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
https://www.verastem.com
Settore/i:
Settore:
Impiegati a tempo pieno: 73
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Daniel W. Paterson | President, CEO & Director | 697,98k | N/D | 1961 |
Mr. Daniel Calkins | CFO and Principal Accounting & Financial Officer | 1,42M | N/D | 1988 |
Mr. Richard H. Aldrich M.B.A. | Founder and Consultant | 38,39k | N/D | 1954 |
Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board | N/D | N/D | N/D |
Dr. Piyush B. Gupta Ph.D. | Co-Founder | N/D | N/D | N/D |
Dr. Michelle Dipp M.D., Ph.D. | Co-Founder | N/D | N/D | 1976 |
Mr. Robert Pintar M.B.A. | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer | 238,18k | N/D | 1958 |
Mr. Nate Sanburn | Senior Vice President of Corporate Development & External Engagement | N/D | N/D | N/D |
Dr. Hagop Youssoufian M.D., M.Sc., Ph.D. | Head of Medical Strategy | N/D | N/D | 1957 |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
L'ISS Governance QualityScore di Verastem, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 8.